ESPE Yearbook of Paediatric Endocrinology

To read the full abstract: N Engl J Med. 2019;381(7):637–46. doi: 10.1056/NEJMoa1903822Short summary: Liraglutide is superior to placebo in improving glycaemic control in children and adolescents with T2DM.Comment: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, also known as an incretin mimetic. It causes glucose-dependent sti...

To read the full abstract: Diabetes Care. 2017;40:1010-1016Professor Tamberlane and co-workers investigated the rates of severe hypoglycemia in the DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort after approximately 30 years of follow-up. In earlier studies, high rates of hypoglycemic episodes had been found to be associated with lower HbA1c levels and intensified insulin ...

To read the full abstract: Pediatr Diabetes. 2020 Mar;21(2):377–383. doi: 10.1111/pedi.12956. PMID: 31808586Across all age groups, management of type 1 diabetes (T1DM) places substantial workload, responsibility and emotional burden, such as worries and stress, on families. This study explored parent perceptions of the burdens of caring for very young children with T1DM. Semi-structured qu...

Brief summary: This study examined glycemic control following treatment with once-weekly exenatide 2 mg (Bydureon, AstraZeneca) in youth with T2D which was not optimally controlled. At 24 weeks, exenatide was superior to placebo in lowering HbA1c (least squares mean change, −0.36% with exenatide vs. +0.49% with placebo), with a between-group difference of −0.85%.Comment: The story of the development of exenatide is fascinating. It starts with...

N Engl J Med 2019; 10.1056/NEJMoa1903822.DOI: 10.1056/NEJMoa1903822http://www.ncbi.nlm.nih.gov/pubmed/31034184Summary: In a double-blind, randomized, phase 3 trial, 135 overweight and obese adolescents, aged 10 to 17 years with T2DM, were randomly assigned to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo, bot...

To read the full abstract: Diabetes Care. 2017;40:1631-1640[Comments on 10.9 and 10.10] These two publications describe guidelines made by the international learned societies on the use of continuous glucose monitoring devices. It is important to learn from these publications that education and guidance are pivotal before continuous glucose...